Phase I open-label study of oral IAG933 in advanced mesothelioma and other solid tumors

Phase 1, open-label trial of IAG933 in mesothelioma, Nonhematologic neoplasms and epithelioid hemangioendothelioma (EHE) (4 arms), sponsored by Novartis. Primary endpoints: Number of patients with adverse events and serious adverse events, Incidence of dose-limiting toxicities during the first treatment cycle and 1 more. Started Oct 2021; status: active, not recruiting.